Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 8/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890589 | 1.00 | GLS (0.43) | GLSMMP2NPC1RAB9AGPR142 | |
| SCHEMBL4949860 | 0.85 | NPC1 (0.52) | GLSNPC1RAB9AGPR142MEN1 | |
| SCHEMBL1244330 | 0.84 | HDAC6 (0.59) | GPR142 | |
| SCHEMBL1244123 | 0.83 | MEN1 (0.48) | MMP2MEN1KMT2AERAP2ERAP1 | |
| SCHEMBL1246092 | 0.83 | SMN1; SMN2 (0.51) | MMP2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1245537 | 0.83 | HDAC3 (0.52) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1246026 | 0.82 | CCNE1 (0.44) | MMP2GPR142 | |
| SCHEMBL1244188 | 0.82 | LTA4H (0.54) | MMP2ERAP2ERAP1LNPEP | |
| SCHEMBL1245373 | 0.80 | HDAC6 (0.61) | — | |
| SCHEMBL1246357 | 0.80 | ALDH1A1 (0.47) | NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893020-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |